Abstract
Cobra Venom Factor (CVF) is the complement-activating protein in cobra venom. CVF is a structural and functional analog of complement component C3. In serum, CVF forms a physicochemically stable and control-resistant C3/C5 convertase that continuously activates C3 and C5, ultimately leading to depletion of serum complement. As CVF can be safely administered to vertebrate animals, it has become an important tool for complement depletion to study the biological functions of complement and its role in the pathogenesis of disease. CVF has also been used for targeted complement activation by chemically coupling it to monoclonal antibodies. Complement depletion is an attractive concept for pharmacological intervention in diseases where complement activation is part of the pathogenetic mechanism. Toward that end, the structural homology of CVF and C3 has been exploited by creating hybrid proteins in which short portions of C3 sequence have been exchanged with corresponding portions of CVF that introduce the desired ability of forming a stable convertase into human C3. These human C3 derivatives are “humanized CVF” proteins that represent an attractive biopharmaceutical for therapeutic complement depletion.
Keywords: Cobra Venom Factor, CVF, complement, complement system, complement depletion, complement inhibition, alternative pathway, C3 convertase, protein humanization
Current Pharmaceutical Design
Title: Humanized Cobra Venom Factor: Experimental Therapeutics for Targeted Complement Activation and Complement Depletion
Volume: 13 Issue: 28
Author(s): Carl-Wilhelm Vogel and David C. Fritzinger
Affiliation:
Keywords: Cobra Venom Factor, CVF, complement, complement system, complement depletion, complement inhibition, alternative pathway, C3 convertase, protein humanization
Abstract: Cobra Venom Factor (CVF) is the complement-activating protein in cobra venom. CVF is a structural and functional analog of complement component C3. In serum, CVF forms a physicochemically stable and control-resistant C3/C5 convertase that continuously activates C3 and C5, ultimately leading to depletion of serum complement. As CVF can be safely administered to vertebrate animals, it has become an important tool for complement depletion to study the biological functions of complement and its role in the pathogenesis of disease. CVF has also been used for targeted complement activation by chemically coupling it to monoclonal antibodies. Complement depletion is an attractive concept for pharmacological intervention in diseases where complement activation is part of the pathogenetic mechanism. Toward that end, the structural homology of CVF and C3 has been exploited by creating hybrid proteins in which short portions of C3 sequence have been exchanged with corresponding portions of CVF that introduce the desired ability of forming a stable convertase into human C3. These human C3 derivatives are “humanized CVF” proteins that represent an attractive biopharmaceutical for therapeutic complement depletion.
Export Options
About this article
Cite this article as:
Vogel Carl-Wilhelm and Fritzinger C. David, Humanized Cobra Venom Factor: Experimental Therapeutics for Targeted Complement Activation and Complement Depletion, Current Pharmaceutical Design 2007; 13 (28) . https://dx.doi.org/10.2174/138161207782023748
DOI https://dx.doi.org/10.2174/138161207782023748 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CYLD-Mediated Signaling and Diseases
Current Drug Targets Release of Adenosine and ATP During Ischemia and Epilepsy
Current Neuropharmacology Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Hematopoietic Progenitor and Stem Cells Circulate by Surfing on Intracellular Ca2+ Waves: A Novel Target for Cell-based Therapy and Anti-cancer Treatment?
Current Signal Transduction Therapy The Link between Exercise and Homocysteine in the Alzheimer’s Disease: A Bioinformatic Network Model
CNS & Neurological Disorders - Drug Targets Understanding the Multifaceted Role of Inflammatory Mediators in Ischemic Stroke
Current Medicinal Chemistry The Role of Dietary Polyphenols in the Management of Inflammatory Bowel Disease
Current Pharmaceutical Biotechnology Epithelial Cell Signaling in Helicobacter pylori Infection
Current Signal Transduction Therapy Inflammation in Cardiovascular Disease and Regulation of the Actin Cytoskeleton in Inflammatory Cells: The Actin Cytoskeleton as a Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Discovery of Lansoprazole and its Unique Pharmacological Properties Independent from Anti-secretory Activity
Current Pharmaceutical Design microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances
Current Molecular Pharmacology Non Invasive Imaging of Myocardial Infarction with Computed Tomography and Magnetic Resonance
Current Vascular Pharmacology Tetracyclines and Neuromuscular Disorders
Current Neuropharmacology TP Receptor as a Therapeutic Target in Atherosclerosis and Related Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Intracerebral Hemorrhage and Diabetes Mellitus: Blood-Brain Barrier Disruption, Pathophysiology and Cognitive Impairments
CNS & Neurological Disorders - Drug Targets Alzheimer's Disease and Natural Products: Future Regimens Emerging from Nature
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Neuroinflammation a Common Link in Neurodegenerative Neurological and Psychiatric Disorders)
Current Pharmaceutical Design Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19
Current Stem Cell Research & Therapy Critical Role of the Endocannabinoid System in the Regulation of Food Intake and Energy Metabolism, with Phylogenetic, Developmental, and Pathophysiological Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets